- In this Newly Created Position, Johnson Will Be Responsible for
Human Capital, Business Processes and Technologies -
BOCA RATON, Fla., Sept. 7 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Joseph Johnson has been
named Senior Vice President, responsible for human capital, business processes
and technologies. He will be based at the company's U.S. headquarters in Boca
Raton, Florida.
In this newly created position, Joe's focus will be in several key areas.
First, in organizational development, he will lead the definition,
recruitment, development and succession planning for key leadership roles in
the company. From an employee perspective, he will direct the development of
performance management, training, and incentive systems aligned with our
strategic plan. He will also lead process development efforts, allowing us to
realize competitive advantages by effectively and efficiently meeting customer
requirements for our innovative products. Finally, he will drive information
technology initiatives to create additional competitive advantages.
Thomas H. McLain, chairman, chief executive officer and president, Nabi
Biopharmaceuticals, stated, "Nabi Biopharmaceuticals is entering a period of
rapid growth and transformation. Joe's expertise in organizational strategy
and talent acquisition will be of tremendous value as we expand to address the
significant commercial opportunities for our products in the U.S. and Europe.
Our products touch the lives of patients around the world every day; our
products in development are poised to completely transform the care and
treatment of serious bacterial infections. The people we attract and retain
as we build a global biopharmaceuticals business are, and will continue to be,
the best in the industry. Joe's insight and experience will be of tremendous
value to our company, our senior leadership and to the achievement of our
goals. We will benefit from Joe's experience and leadership in the
biopharmaceutical industry in terms of organization, strategy and enabling
commercial execution."
Mr. Johnson most recently served as the Practice Leader for Human Capital
Strategy at IBM Business Consulting Services, supporting the firm's
biopharmaceutical industry practice. He has over 15 years of experience in
designing, implementing and managing a wide variety of human capital programs,
including complex global initiatives and acquisitions in the pharmaceutical
and biopharmaceutical industries. Mr. Johnson has provided organizational
strategy, compensation strategy, leadership guidance, and change management
strategy for boards of directors and executive management at 11 of the Fortune
25 companies. Before joining IBM, Mr. Johnson was a partner at Arthur D.
Little, the oldest consulting firm in the U.S. At the firm, his client roster
included: Biogen, Genzyme, Amgen, AstraZeneca, Serono, Johnson & Johnson,
Novartis, Wyeth, Roche, Teva, Chiron, Genentech, Bristol Myers,
GlaxoSmithKline, and Merck.
Mr. Johnson began his career in human capital consulting working for
Cambria Consulting, a firm that was founded by Harvard professors David Norton
and George Klemp and was later absorbed by KPMG. Prior to working as a
consultant, Mr. Johnson was in investment banking at Lehman Brothers, where he
focused on biotechnology.
Mr. Johnson graduated summa cum laude from The College of the Holy Cross
with a Bachelor of Arts degree in English.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are poised to capture large, commercial opportunities in our
core business areas: Gram-positive bacterial infections, hepatitis, and kidney
disease (nephrology), and opportunistically in nicotine addiction. We have
three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
preclinical development. The company filed its Marketing Authorization
Application (MAA) in Europe for its product candidate, StaphVAX(R)
[Staphylococcus aureus Polysaccharide Conjugate Vaccine], in December 2004.
The application was accepted for review in January 2005. StaphVAX is
currently in a confirmatory Phase III clinical trial in the United States.
StaphVAX is designed to prevent the most dangerous and prevalent strains of S.
aureus bacterial infections. S. aureus bacteria are a major cause of
hospital-acquired infections and are becoming increasingly resistant to
antibiotics. The company also filed MAA's in Europe to market Nabi-HB(R)
Intravenous [Hepatitis B Immune Globulin (Human) Intravenous] under the trade
name HEBIG(TM) for the prevention of hepatitis B disease in HBV-positive liver
transplant patients; and for PhosLo(R) (calcium acetate), which is already
marketed in the U.S. The company's other products in development include
Altastaph(TM) [Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for prevention and treatment of S. aureus infections, NicVAX(TM)
[Nicotine Conjugate Vaccine], a vaccine to treat nicotine addiction, and
Civacir(TM) [Hepatitis C Immune Globulin (Human)], an antibody for preventing
hepatitis C virus re-infection in liver transplant patients. For additional
information on Nabi Biopharmaceuticals, please visit our website at
http://www.nabi.com .
This press release contains forward-looking statements that reflect the
company's current expectations regarding future events. Any such forward-
looking statements are not guarantees of future performance and involve
significant risks and uncertainties. Actual results may differ significantly
from those in the forward-looking statements as a result of any number of
factors, including, but not limited to, risks relating to the possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans to
commercialize StaphVAX in the European Union and United States may not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional capital on
acceptable terms; the company's dependence upon third parties to manufacture
its products; the company's ability to utilize the full capacity of its
manufacturing facility; the impact on sales of Nabi-HB from patient treatment
protocols and the number of liver transplants performed in HBV-positive
patients; reliance on a small number of customers; the future sales growth
prospects for the company's biopharmaceutical products; and the company's
ability to obtain regulatory approval for its products in the United States or
abroad or to successfully develop, manufacture and market its products. These
factors are more fully discussed in the company's Annual Report on Form 10-K
for the fiscal year ended December 25, 2004 filed with the Securities and
Exchange Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Constance C. Bienfait, Vice President,
Investor Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
